252 related articles for article (PubMed ID: 34199285)
1. Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma.
Watanabe T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199285
[TBL] [Abstract][Full Text] [Related]
2. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Horenstein AL; Bracci C; Morandi F; Malavasi F
Front Immunol; 2019; 10():760. PubMed ID: 31068926
[TBL] [Abstract][Full Text] [Related]
3. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
4. Extracellular Vesicles Enhance Multiple Myeloma Metastatic Dissemination.
Colombo M; Giannandrea D; Lesma E; Basile A; Chiaramonte R
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31266187
[TBL] [Abstract][Full Text] [Related]
5. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD
Morandi F; Marimpietri D; Horenstein AL; Bolzoni M; Toscani D; Costa F; Castella B; Faini AC; Massaia M; Pistoia V; Giuliani N; Malavasi F
Oncoimmunology; 2018; 7(8):e1458809. PubMed ID: 30221054
[TBL] [Abstract][Full Text] [Related]
6. The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment.
Khalife J; Sanchez JF; Pichiorri F
Front Oncol; 2021; 11():689538. PubMed ID: 34235082
[TBL] [Abstract][Full Text] [Related]
7. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
Tang W; Xu J; Xu C
Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
[No Abstract] [Full Text] [Related]
9. Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.
Costa F; Toscani D; Chillemi A; Quarona V; Bolzoni M; Marchica V; Vescovini R; Mancini C; Martella E; Campanini N; Schifano C; Bonomini S; Accardi F; Horenstein AL; Aversa F; Malavasi F; Giuliani N
Oncotarget; 2017 Aug; 8(34):56598-56611. PubMed ID: 28915615
[TBL] [Abstract][Full Text] [Related]
10. Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma.
Horenstein AL; Morandi F; Bracci C; Pistoia V; Malavasi F
Immunol Lett; 2019 Jan; 205():40-50. PubMed ID: 30447309
[TBL] [Abstract][Full Text] [Related]
11. Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression.
Saltarella I; Lamanuzzi A; Apollonio B; Desantis V; Bartoli G; Vacca A; Frassanito MA
Cells; 2021 Nov; 10(11):. PubMed ID: 34831408
[TBL] [Abstract][Full Text] [Related]
12. CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents.
Costa F; Dalla Palma B; Giuliani N
Cells; 2019 Dec; 8(12):. PubMed ID: 31847204
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicles from human umbilical cord blood plasma modulate interleukin-2 signaling of T cells to ameliorate experimental autoimmune encephalomyelitis.
Kim S; Maeng JY; Hyun SJ; Sohn HJ; Kim SY; Hong CH; Kim TG
Theranostics; 2020; 10(11):5011-5028. PubMed ID: 32308765
[TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
15. Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.
Horenstein AL; Quarona V; Toscani D; Costa F; Chillemi A; Pistoia V; Giuliani N; Malavasi F
Mol Med; 2016 Dec; 22():694-704. PubMed ID: 27761584
[TBL] [Abstract][Full Text] [Related]
16. Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche.
Chillemi A; Quarona V; Antonioli L; Ferrari D; Horenstein AL; Malavasi F
Front Immunol; 2017; 8():305. PubMed ID: 28373875
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.
Asimakopoulos F; Hope C; Johnson MG; Pagenkopf A; Gromek K; Nagel B
J Leukoc Biol; 2017 Aug; 102(2):265-275. PubMed ID: 28254840
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
Zarfati M; Avivi I; Brenner B; Katz T; Aharon A
Angiogenesis; 2019 Feb; 22(1):185-196. PubMed ID: 30386953
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.
Quarona V; Ferri V; Chillemi A; Bolzoni M; Mancini C; Zaccarello G; Roato I; Morandi F; Marimpietri D; Faccani G; Martella E; Pistoia V; Giuliani N; Horenstein AL; Malavasi F
Ann N Y Acad Sci; 2015 Jan; 1335():10-22. PubMed ID: 25048519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
